SCHEMBL1660150

SCHEMBL1660150

O=C(OC(=O)c1ccc(O)cc1)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.64
LMNA P02545 4/20 0.60
ESR1 P03372 5/20 0.58
ESR2 Q92731 5/20 0.58
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
MAPT P10636 2/20 0.57
RAB9A P51151 1/20 0.57
F2 P00734 1/20 0.56
CA12 O43570 4/20 0.56
CA1 P00915 4/20 0.56
CA2 P00918 4/20 0.56
CA7 P43166 4/20 0.56
CA9 Q16790 4/20 0.56
CA14 Q9ULX7 4/20 0.56
MIF P14174 1/20 0.53
CA3 P07451 1/20 0.52
TYR P14679 1/20 0.52
DRD1 P21728 1/20 0.52
CA4 P22748 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22345808 0.98 CES2 (0.61) CES2LMNAESR1ESR2KMT2A
Hydroquinone SCHEMBL18144646 0.98 CES2 (0.60) CES2LMNAESR1ESR2KMT2A
Biphenyl SCHEMBL10761998 0.91 ESR1 (0.59) CES2LMNAESR1ESR2KMT2A
SCHEMBL5669277 0.91 CA1 (0.65) CES2LMNAESR1ESR2KMT2A
SCHEMBL8717537 0.91 LMNA (0.67) CES2LMNAKMT2AMAPTF2
Hydrogen Peroxide SCHEMBL27952375 0.88 LMNA (0.70) CES2LMNAKMT2AMAPTF2
Benzene SCHEMBL27793442 0.88 LMNA (0.70) CES2LMNAKMT2AMAPTF2
SCHEMBL52413 0.88 LMNA (0.70) CES2LMNAKMT2AMAPTF2
SCHEMBL7617231 0.86 LMNA (0.77) CES2LMNAESR1ESR2KMT2A
SCHEMBL2591454 0.85 LMNA (0.67) CES2LMNAKMT2AMAPTF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115297858-B Pharmaceutical composition for treating hypertrophic cardiomyopathy and treatment method using the same 赛特瑞恩股份有限公司 2024-08-13 CN claimed
CN-115297858-A Pharmaceutical composition for treating hypertrophic cardiomyopathy and treatment method using same 赛特瑞恩股份有限公司 2022-11-04 CN claimed
CN-107522669-B 1 antagonist of transient receptor potential vanillic acid hypotype and its preparation method and application 重庆美莱德生物医药有限公司 2019-12-03 CN claimed
CN-107522668-B TRPV1 antagonist and its preparation method and application 重庆医科大学 2019-12-03 CN claimed
WO-2018095353-A1 SALTS OF AMINOQUINAZOLINE DERIVATIVE AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-05-31 WO claimed
US-7304182-B2 Crystalline parahydroxybenzoic acid anhydride and process for preparing the same KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (JP) 2007-12-04 US claimed
US-20060264670-A1 Crystal of p-hydroxybenzoic anhydride and process for producing the same UENO FINE CHEMICALS INDUSTRY, LTD. (JP) 2006-11-23 US claimed
EP-1614673-A1 CRYSTAL OF p-HYDROXYBENZOIC ANHYDRIDE AND PROCESS FOR PRODUCING THE SAME KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (JP) 2006-01-11 EP claimed
US-4380587-A Film badge for determining carbonyl compounds ARTHUR D. LITTLE, INC. (US) 1983-04-19 US claimed
US-12421204-B2 Process for preparing chroman compounds LUPIN LIMITED (IN) 2025-09-23 US disclosed
CN-111065623-B9 Linker for antibody drug conjugates 德克萨斯州大学系统董事会 2024-10-25 CN disclosed
CN-114286818-B Heterocyclic compounds as BET inhibitors 诺维逊生物股份有限公司 2024-09-20 CN disclosed
CN-118652192-A Linker for antibody drug conjugates 德克萨斯州大学系统董事会 2024-09-17 CN disclosed
CN-111065623-B Linker for antibody drug conjugates 德克萨斯州大学系统董事会 2024-09-03 CN disclosed
EP-0155593-B1 FLUORAN COMPOUNDS AND RECORDING SHEETS CONTAINING THEM KANZAKI PAPER MANUFACTURING CO., LTD (JP) 1988-09-07 EP disclosed
US-4629800-A PRESSURE, HEAT AND ELECTROTHERMAL SENSITIVE RECORDING SHEETS; COLOR BLACK KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1986-12-16 US disclosed
EP-0155593-A2 Fluoran compounds and recording sheets containing them KANZAKI PAPER MANUFACTURING CO., LTD (JP) 1985-09-25 EP disclosed
US-4232026-A Diazaditwistanes, and pharmaceutical compositions for treating pain in warm blooded animals containing them MERCK & CO., INC. (US) 1980-11-04 US disclosed
US-3985720-A Polymerization of ethylenically unsaturated monomer employing a catalyst system comprising dialkylpyrocarbonate, organic acid anhydride, alkaline reagent and H2 O2 PPG INDUSTRIES, INC. (US) 1976-10-12 US disclosed
US-3978032-A ALKALINE BUFFER, ANHYDRIDE, PERACID, ALKYL HALOFORMATE PPG INDUSTRIES, INC. (US) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421204-B2 Process for preparing chroman compounds CASR, P2RY4, ITPR1 CES2 2776/4885LMNA 3624/4885ESR1 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.